ChemoCentryx reported $10.96M in Gross Profit on Sales for its second fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Gross Profit On Sales Change
Alnylam Pharmaceuticals ALNY:US USD 223.19M 39.18M
Amgen AMGN:US USD 5.06B 20M
AstraZeneca AZN:LN USD 8.86B 3M
Bayer BAYN:GR EUR 7.03B 105M
Biogen BIIB:US USD 2.04B 66.1M
Biomarin Pharmaceutical BMRN:US USD 389.06M 21.62M
Bristol Myers Squibb BMY:US USD 8.86B 345M
Glaxosmithkline GSK:US GBP 5.44B 650M
GlaxoSmithKline GSK:LN GBP 5.44B 650M
Johnson & Johnson JNJ:US USD 15.98B 134M
MacroGenics MGNX:US USD 38.59M 14.99M
Merk MRK:US USD 11.52B 1.08B
Novartis NOVN:VX USD 9.18B 151M
Pfizer PFE:US USD 16.55B 2.52B
Roche Holding ROG:VX 22.73B 924M
Sarepta Therapeutics SRPT:US USD 190.32M 5.38M
Takeda 4502:JP JPY 696.86B 17.28B
Teva Pharmaceutical TEVA:IT USD 1.71B 118M
YTE INCY:US USD 774.02M 92.14M